ArticleBioinformation2026
Treatment outcomes and clinical characteristics in diabetic versus non-diabetic sinonasal tuberculosis.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sinonasal tuberculosis (SNTB) is a rare extrapulmonary presentation with poorly understood interplay with diabetes mellitus (DM). Therefore, it is of interest to compare the clinical presentation, microbiological characteristics and treatment outcomes between 60 patients with DM with SNTB and 60 non-diabetic controls treated in one of the tertiary referral centers. DM patients had a longer duration of symptoms (18.4±6.2 vs 11.2±4.1 weeks, p=0.001), more complications (41.7% vs 18.3% p=0.004) and more disease on imaging (bony involvement: 55.0% vs 31.7, p=0.011). The culture positivity (78.3 vs 58.3, p=0.015) and drug resistance (multidrug- resistance: 15.0 vs 3.3, p=0.026) were more positive in microbiologically positive patients of DM. The results of treatment showed slower conversion of sputum in DM patients (8.3±2.1 vs 6.1±1.8 weeks, p<0.001), longer therapy period (9.8±1.2 vs 8.2±0.9 months, p<0.001) and reduced success rates (78.3% vs 91.7, p=0.032). Thus, outcome success was negatively related to glycemic control (r= -0.67, p=0.001).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.